Genmab A/S (GMAB) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 12 Buy, 4 Hold, 1 Sell.
The consensus price target is $42.13 (low: $39.00, high: $48.00), representing an upside of 45% from the current price $29.06.
Analysts estimate Earnings Per Share (EPS) of $0.19 and revenue of $0.47B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $12.14 vs est $0.19 (beat +6399.7%). 2025: actual $1.55 vs est $0.27 (beat +478.6%). Analyst accuracy: 9%.
GMAB Stock — 12-Month Price Forecast
$42.13
▲ +44.98% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Genmab A/S, the average price target is $42.13, with a high forecast of $48.00, and a low forecast of $39.00.
The average price target represents a +44.98% change from the last price of $29.06.
Highest Price Target
$48.00
Average Price Target
$42.13
Lowest Price Target
$39.00
GMAB Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Genmab A/S in the past 3 months
EPS Estimates — GMAB
9%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $12.14
vs Est $0.19
▲ 98.5% off
2025
Actual $1.55
vs Est $0.27
▲ 82.7% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is declining.
Revenue Estimates — GMAB
9%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $21.526B
vs Est $0.465B
▲ 97.8% off
2025
Actual $3.723B
vs Est $0.576B
▲ 84.5% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast revenue contraction ahead.
